Delivering Therapy Where it Matters

TIGeR-PaC Phase 3
Clinical Trial Now Enrolling

Standard treatments for pancreatic cancer are often ineffective as they cannot be directly delivered to the tumor.

A promising potential new option for targeted treatment is being studied in a clinical trial intended to investigate its effect on reducing the chances of the cancer spreading and extending survival, while improving quality of life.

Introducing RenovoRx’s
Trans-Arterial Micro-Perfusion (RenovoTAMP™)

RenovoTAMP is the Company’s novel therapy platform designed to deliver well-established chemotherapeutic agents for localized treatment of solid cancer tumors and is under investigation to increase survival and improve quality of life. This platform technology will enable physicians to isolate the anatomy and micro-perfuse targeted tissue with small molecule chemotherapy.

The TIGeR-PaC clinical trial is a randomized study utilizing the RenovoTAMP platform.

Unlike other treatments that are given systemically or intravenously (IV), with RenovoTAMP, the chemotherapy is delivered directly into the pancreas via the arteries closest to the tumor. This innovative therapy utilizes RenovoRx’s lead product candidate, RenovoGem (intra-arterial gemcitabine delivered in combination with FDA-cleared and patented RenovoCath delivery system).*

Latest News

Menu